Smoking status and the baseline international index of erectile function score can predict satisfactory response to platelet‐rich plasma in patients with erectile dysfunction: A prospective pilot study

Abstract

Erectile dysfunction (ED) is a common condition with a significant impact on the quality of life. Regenerative medicine maladies are intended to repair or replace damaged tissues and organs through different therapeutic mechanisms. Our aim was to study the effect of intra‐corporeal injection (ICI) of platelet‐rich plasma (PRP) in ED patients. Thirty‐four patients’ erectile function was evaluated by filling up an abridged form of the international index of erectile function (IIEF‐5) before and after PRP therapy. ICI of PRP was done once per week for 2 months. All patients were prescribed PDE5Is for one month after PRP therapy. Penile haemodynamics was assessed using 20 µg of PGE1 before and 3 months after initiating PRP therapy. Interestingly, our study had shown that there was a statistically significant difference in the IIEF‐5 score after ICI of PRP (−5.5, ±5.2, p=<0.001). Furthermore, in multiple logistic regression model for PRP responsiveness, smoking and IIEF score before PRP were the only significant independent variables (p = .040, p = .023 respectively). PRP injection for ED patients may be a promising modality as well as baseline IIEF‐5, and smoking status can be used as predictors for a satisfactory response to PRP in such patients.

Assessment of the intracavernosal injection platelet‐rich plasma in addition to daily oral tadalafil intake in diabetic patients with erectile dysfunction non‐responding to on‐demand oral PDE5 inhibitors

“…(2021) reported that cavernous PRP therapy in ED cases is reliable but although the mean IIEF‐EF scores were significantly increased, the ED grades were the same. Moreover, Zaghloul et al (2021) demonstrated that cavernous PRP injection for ED patients could be a encouraging modality where baseline IIEF‐5 and smoking status were predictors for such satisfactory reaction.…”

“…ICI was carried out over 4 injection points, 2 on each side of the penis (one in the proximal third and one in the middle third) using a 5/16 inch 28G needle (Figure 1) followed by applied pressure to the injection site and the root of the penis for 1–2 min to avoid rapid washout of the material. Massage of the penis was carried out for 1–2 min to distribute the material into the penis (Zaghloul et al, 2021). Both groups were given a daily dose of 5 mg tadalafil plus vardenafil 20 mg on demand during the entire study. All cases were evaluated at baseline, and 12 weeks after PRP injections by: IIEF‐5 Questionnaire no (ED [total score, 22–25], mild ED [17–21], mild‐moderate ED [12–16], moderate ED [8–11] and severe ED [5–7]) (Cappelleri & Rosen, 2005).…”

“…ICI was carried out over 4 injection points, 2 on each side of the penis (one in the proximal third and one in the middle third) using a 5/16 inch 28G needle (Figure 1) followed by applied pressure to the injection site and the root of the penis for 1-2 min to avoid rapid washout of the material. Massage of the penis was F I G U R E 1 Platelet-rich plasma (PRP) injectable sites carried out for 1-2 min to distribute the material into the penis (Zaghloul et al, 2021).…”

“…Several preclinical and clinical trials were designated in using autologous PRP for treating ED with a limitation of small groups and short follow‐up periods (Chung, 2021; Zaghloul et al, 2021). The main outcome measures for those preclinical trials on ED were erectile function, evaluated with intracavernosal pressure and histopathology of the cavernous tissue (Poulios et al, 2021; Wu et al, 2021).…”

Erectile dysfunction: Is platelet-rich plasma the new frontier for treatment in patients with erectile dysfunction? A review of the existing evidence

“…Zaghlou et al examined the effects of smoking status and baseline IIEF5 in the response to PRP ( 39 ). The study was aimed to evaluate the effect of PRP ICI in men with ED whose ED was not responsive to PDE5i oral medication (including daily and on-demand regimes).…”